NCT00125736

A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 520 (actual)
• Sponsor: Eisai Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer.

Detailed description

The efficacy and safety of E0671 in combination with Rabeprazole Sodium (i.e., 10 mg/day of rabeprazole sodium and 150 mg/day of E0671) will be investigated in patients with gastric ulcer in a multicenter, randomized, double-blind, parallel-group comparative study using a placebo control group (10 mg/day of rabeprazole sodium and placebo for E0671).

Conditions

• Stomach Ulcer

Interventions

Type	Name	Description
DRUG	E0671	One 50 mg capsule is orally administered three times daily (150 mg/day)
DRUG	rabeprazole sodium	One 10mg tablet is administered orally each day
DRUG	E0671 placebo	One 50 mg capsule is orally administered three times daily (150 mg/day)

Timeline

• Start date: 2005-08-01
• Primary completion: 2007-04-19
• Completion: 2007-04-19
• First posted: 2005-08-02
• Last updated: 2018-10-29

Locations

43 sites across 1 country: Japan